These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30338683)

  • 21. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
    Boden WE; Bhatt DL
    Circulation; 2018 Aug; 138(9):858-860. PubMed ID: 30354448
    [No Abstract]   [Full Text] [Related]  

  • 22. Role of aspirin in MATCH.
    Bath P
    Lancet; 2004 Nov 6-12; 364(9446):1662; author reply 1662-3. PubMed ID: 15530618
    [No Abstract]   [Full Text] [Related]  

  • 23. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
    Jackson LR; Ju C; Zettler M; Messenger JC; Cohen DJ; Stone GW; Baker BA; Effron M; Peterson ED; Wang TY
    JACC Cardiovasc Interv; 2015 Dec; 8(14):1880-9. PubMed ID: 26718518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cerebral secondary prevention--clopidogrel alone or in combination with ASS].
    Nitschmann S; Hartung HP; Siebler M
    Internist (Berl); 2005 Nov; 46(11):1278-82. PubMed ID: 16211404
    [No Abstract]   [Full Text] [Related]  

  • 25. Lessons from MATCH for future randomised trials in secondary prevention of stroke.
    Rothwell PM
    Lancet; 2004 Jul 24-30; 364(9431):305-7. PubMed ID: 15276368
    [No Abstract]   [Full Text] [Related]  

  • 26. Stroke prevention: antiplatelet and antithrombolytic therapy.
    Diener HC
    Haemostasis; 2000; 30 Suppl 3():14-26. PubMed ID: 11182625
    [No Abstract]   [Full Text] [Related]  

  • 27. [The ISAR-SAFE study].
    Capranzano P; Castiglioni B
    G Ital Cardiol (Rome); 2015 Jun; 16(6):331-5. PubMed ID: 26156693
    [No Abstract]   [Full Text] [Related]  

  • 28. Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.
    Bagai A; Bhatt DL; Eikelboom JW; Mancini GB; Cohen EA; Vijayaraghavan R; Cheema AN; Udell JA; Niznick J; Tanguay JF; Verma S; Mehta SR
    Circulation; 2016 May; 133(21):2094-8. PubMed ID: 27217435
    [No Abstract]   [Full Text] [Related]  

  • 29. Pro: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
    Healey JS
    Thromb Haemost; 2009 Nov; 102(5):912-3. PubMed ID: 19888528
    [No Abstract]   [Full Text] [Related]  

  • 30. Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
    Apostolakis S; Shantsila E; Lip GY; Lane DA
    Thromb Haemost; 2009 Nov; 102(5):914-5. PubMed ID: 19888529
    [No Abstract]   [Full Text] [Related]  

  • 31. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Costa F; van Klaveren D; James S; Heg D; Räber L; Feres F; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Zanchin T; Palmerini T; Wallentin L; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
    Lancet; 2017 Mar; 389(10073):1025-1034. PubMed ID: 28290994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
    Pandit A; Giri S; Hakim FA; Fortuin FD
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial.
    Søgaard M; Nielsen PB; Skjøth F; Larsen TB; Eldrup N
    Eur J Vasc Endovasc Surg; 2022 Feb; 63(2):285-294. PubMed ID: 34924303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation.
    Hess CN; Peterson ED; Peng SA; de Lemos JA; Fosbol EL; Thomas L; Bhatt DL; Saucedo JF; Wang TY
    J Am Coll Cardiol; 2015 Aug; 66(6):616-27. PubMed ID: 26248987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A look back: the quest for thrombosis in heart failure continues after COMMANDER HF.
    Filippatos G; Farmakis D
    Cardiovasc Res; 2019 Nov; 115(13):e140-e142. PubMed ID: 31638158
    [No Abstract]   [Full Text] [Related]  

  • 38. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38).
    Hochholzer W; Wiviott SD; Antman EM; Contant CF; Guo J; Giugliano RP; Dalby AJ; Montalescot G; Braunwald E
    Circulation; 2011 Jun; 123(23):2681-9. PubMed ID: 21606391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.